bluuebunny/crossref_metadata_2025_split huggingface dataset:
Gestational Diabetes (GDM) and Childhood Disorders of Glucose Metabolism—Hyperglycemia and Adverse Pregnancy Outcome Follow-Up Study (HAPO FUS)
Authors: BRICKMAN WENDY , CATALANO PATRICK , CLAYTON PETER E. , DEEROCHANAWONG CHAICHARN , HAMILTON JILL , LASHLEY PAULA M. , LAWRENCE JEAN M. , LEBENTHAL YAEL , MCCANCE DAVID R. , TAM WING H. , KUANG ALAN , LOWE LYNN P. , METZGER BOYD E. , SCHOLTENS DENISE , LOWE WILLIAM ,   HAPO FOLLOW-UP STUDY COOPERATIVE RESEARCH GROUP
Published: June 2018

While overt diabetes during pregnancy is associated with a higher childhood risk of altered glucose metabolism, the contribution of GDM to this disorder is less clear. Using data from HAPO FUS, we examined associations of maternal GDM not confounded by treatment with childhood glucose metabolism. Maternal glycemic status was based on a 75 g oral glucose tolerance test (OGTT) at ∼28 weeks gestation. Offspring disorders of glucose metabolism (impaired glucose tolerance or type 2 diabetes using American Diabetes Association criteria) were assessed at the HAPO FUS visit using an OGTT in 41children at mean age 11.4 (range 7.9-15.5) years. Insulin sensitivity (IS) was calculated using the Matsuda index and insulin secretion using the insulinogenic index. GDM was defined by International Association of Diabetes in Pregnancy Study Groups criteria. Among offspring of mothers with and without GDM, 10.6% and 5.2%, respectively, had a disorder of glucose metabolism. After adjusting for field center, maternal pregnancy variables and child age, Tanner stage and family history of diabetes at HAPO FUS, the odds ratio and 95% confidence interval (CI) for a disorder of glucose metabolism was 1.98 (1.44-2.74), p=3.1 x 10-5. Adjusting for maternal BMI at OGTT, child’s BMI z score, or both did not attenuate risk. Offspring of GDM mothers had lower IS (29.7 ± 12.5, mean ± SD) compared to offspring of non-GDM mothers (33.7 ± 13.8) with a mean difference of -2.1 (95% CI -3.2 - -1.0), p= 1.9 x 10-4 after adjusting for field center, maternal pregnancy variables and child age, Tanner stage and family history of diabetes at HAPO FUS. The association was attenuated but still significant after adjusting for maternal BMI and/or child BMI z score. Maternal GDM was not associated with insulinogenic index.
In summary, exposure to untreated GDM in utero is significantly and independently associated with childhood disorders of glucose metabolism, in part through insulin resistance.

Disclosure
W. Brickman: None. P. Catalano: None. P.E. Clayton: None. C. Deerochanawong: None. J. Hamilton: None. P.M. Lashley: None. J.M. Lawrence: None. Y. Lebenthal: Speaker's Bureau; Self; Novo Nordisk Inc.. Consultant; Self; Kamada. D.R. McCance: None. W.H. Tam: None. A. Kuang: None. L.P. Lowe: None. B.E. Metzger: None. D. Scholtens: None. W. Lowe: None.
Type 2 Diabetes Mellitus (T2DM) Patients with Inadequate A1C Control on Metformin (MET) + DPP-4i—A Network Meta-analysis (NMA) of the Efficacy and Safety of SGLT2i, GLP-1 Analogs, and Insulin
Authors: MCNEILL ANN MARIE , DAVIES GLENN M. , KRUGER ELIZA , KOWAL STACEY L. , EJZYKOWICZ FLAVIA , HANNACHI HAKIMA , CATER NILO B. , MCLEOD EUAN 
Published: June 2018

Objective: Indirectly compare the efficacy and safety of ertugliflozin (ERTU) from the VERTIS SITA2 trial to other treatments in patients with inadequate A1C control on MET+DPP-4i.
Methods: Literature was searched up to end 2016 for RCTs in patients with A1C ≥7% on MET+DPP-4i. Included outcomes vs. placebo at 24-26 weeks were change in A1C, weight, systolic blood pressure, A1C &lt;7%, urinary tract infections, genital mycotic infections, hypoglycemia and patients with ≥1 adverse event. Evidence synthesis used fixed effect and random effects Bayesian NMA, with model selection informed by guidelines. Credible intervals (CrI), analogous to 95% confidence intervals, were used to determine significance.
Results: Interventions compared (+background therapies) were dapagliflozin 10mg (MET+sitagliptin [SITA] and MET+saxagliptin), empagliflozin 10/25mg (MET+linagliptin), titrated canagliflozin (MET+SITA), titrated liraglutide (MET) and ERTU 5/15mg (MET+SITA). No relevant insulin RCTs were found. Added to MET+SITA, ERTU 5 and 15mg were significantly more effective than dapagliflozin 10mg (A1C mean difference [MD] 5mg -0.29%, CrI -0.56, -0.02; 15mg -0.37%, CrI -0.64, -0.10). Comparisons to other SGLT2i regimens did not find significant differences in A1C or other outcomes. The liraglutide arm of LIRA SWITCH discontinued SITA. Sensitivity analysis comparing triple therapy (MET+SITA+ERTU) vs. dual therapy (MET+liraglutide) did not find significant differences (A1C MD 5mg -0.07%, CrI -0.35, 0.22, 15mg -0.15% CrI -0.43, 0.14).
Conclusions: Amongst patients requiring triple therapy with SGLT2i added to MET+DPP-4i there was considerable heterogeneity between studies and assumptions of equivalence of background DPP-4i were required. Nonetheless, this analysis indicated that ERTU was more effective than dapagliflozin as add-on to MET+SITA and was comparable to other SGLT2i+MET+DPP-4i regimens.

Disclosure
A. McNeill: Employee; Self; Merck & Co., Inc.. Stock/Shareholder; Self; Merck & Co., Inc. G.M. Davies: Employee; Self; Merck & Co., Inc. E. Kruger: Employee; Self; QuintilesIMS. S.L. Kowal: None. F. Ejzykowicz: Employee; Self; Merck Sharp & Dohme Corp. H. Hannachi: Employee; Self; Merck & Co., Inc. N.B. Cater: Employee; Self; Peter Sheehan Diabetes Care Foundation, Inc. E. McLeod: Employee; Self; Pfizer Inc..
Changes in Energy Balance during Dapagliflozin Therapy in Type 2 Diabetes—The Energize Study
Authors: RAJEEV SURYA PANICKER , ROBERTS CARL A. , CUTHBERTSON DANIEL J. , SPRUNG VICTORIA S. , BROWN EMILY , HALFORD JASON C. , HARROLD JOANNE A. , KEMP GRAHAM J. , STANCAK ANDREJ , WILDING JOHN P. 
Published: June 2018

Weight loss during SGLT2i therapy is less than predicted from urinary glucose loss. Modelling suggests a 10-15% compensatory increase in energy intake. We compared effects of 12 weeks’ dapagliflozin 10mg od vs. placebo on food intake in a double-blind, placebo-controlled study with short (1 week) and long-term (12 week) crossover periods. Food intake was measured during test meals at baseline, pre and post each crossover using the Sussex Ingestion Pattern Monitor, continuously recording intake during the meal; primary outcome was the difference after 12 weeks’ treatment. 52 patients with T2DM treated with diet or oral agents were recruited (45 completed;43% female). Median age 60y, weight 98.4 kg, BMI 34, HbA1c 59.5 mmol/mol. Analysis used a linear mixed model with the random effect as study subject and fixed effects of sex, visit, study arm and arm:visit interaction. Dapagliflozin use was associated with a reduction in HbA1c -9.73mmol/mol (95% CI 3.91, 16.27; p=0.004), and body weight (-2.84 vs. -0.87 kg) vs. placebo. There was no difference in test meal food intake between dapagliflozin and placebo at 12 weeks median difference, 2.63g (95% CI,-31.65,36.9); p=0.659 or at other time points. Dapagliflozin was not associated with a compensatory increase in food intake.

Disclosure
S. Rajeev: None. C.A. Roberts: None. D.J. Cuthbertson: None. V.S. Sprung: None. E. Brown: Research Support; Self; AstraZeneca. J.C. Halford: Advisory Panel; Self; Novo Nordisk A/S. Speaker's Bureau; Self; Novo Nordisk A/S. J.A. Harrold: None. G.J. Kemp: None. A. Stancak: None. J.P. Wilding: Other Relationship; Self; Astellas, AstraZeneca, Boehringer Ingelheim GmbH, Janssen Pharmaceuticals, Inc., Novo Nordisk Inc., Sanofi, Eli Lilly and Company, Orexigen Therapeutics, Inc., Merck & Co., Inc..
Evaluation of Osmotic Diuresis and Volume Depletion Events in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Ertugliflozin
Authors: PATEL SHRITA M. , HICKMAN MARY A. , FREDERICH ROBERT , LAURING BRETT , TERRA STEVEN , JOHNSON SUSAN L. , HUYCK SUSAN , MANCUSO JAMES P. 
Published: June 2018

Ertugliflozin (ERTU) is an SGLT2 inhibitor for the treatment of T2DM. Osmotic diuresis (OD), volume depletion (VD) and change in renal function were assessed in adults with T2DM. Pooled analyses were performed on data from 7 randomized, double blind, Phase 3 trials in patients receiving ERTU or non-ERTU (placebo [PBO] or active comparator) for at least 26 weeks, including a PBO pool (subset; n=1544) and a broad pool (all studies; N=4859; ERTU 5 mg: n=1716; ERTU 15 mg: n=1693; non-ERTU: n=1450). Mean age was 57.8 years, 25.8% were ≥65 years old, 51.8% were male and 27.7% were on diuretics. Mean eGFR was 85.3 mL/min/1.73 m2. Mean duration of T2DM was 7.9 years and mean baseline (BL) A1C was 8.2%. BL characteristics were similar in the PBO pool.
In the broad pool, the incidence of OD events was 2.7%, 2.2%, and 1.4% with ERTU 5 mg, ERTU 15 mg, and non-ERTU, respectively; none were serious and ≤0.2% led to treatment discontinuation. The incidence of VD events was 1.9%, 1.4%, and 1.2% with ERTU 5 mg, ERTU 15 mg and non-ERTU, respectively; 0.2%, 0% and 0%, respectively, were serious and ≤0.1% led to treatment discontinuation. In patients with moderate renal impairment (RI; n=575, ∼12%), ≥65 years old, or on diuretics, ERTU led to a higher incidence of VD events than non-ERTU. In the PBO pool, the incidence of OD events was 2.9%, 2.4%, and 1.0% and the incidence of VD events was 0.8%, 1.0%, and 1.7% with ERTU 5 mg, ERTU 15 mg and PBO, respectively. There was no increase in the proportion of patients with orthostatic hypotension with ERTU treatment.
ERTU was associated with small, early decreases in eGFR that returned to or towards BL during treatment. Mean decreases in eGFR were larger in patients with BL moderate RI and returned to BL after treatment discontinuation (recently published).
ERTU is associated with OD, but does not generally lead to VD events or orthostatic hypotension. Consistent with this, observed decreases in eGFR were reversible during treatment or after discontinuation.

Disclosure
S.M. Patel: Employee; Self; Merck & Co., Inc.. Employee; Spouse/Partner; GlaxoSmithKline plc.. Stock/Shareholder; Self; Merck & Co., Inc.. Stock/Shareholder; Spouse/Partner; GlaxoSmithKline plc. M.A. Hickman: Employee; Self; Pfizer Inc.. Stock/Shareholder; Self; Pfizer Inc. R. Frederich: Employee; Self; Pfizer Inc.. Stock/Shareholder; Self; Pfizer Inc., Bristol-Myers Squibb Company. B. Lauring: Employee; Self; Merck & Co., Inc. S. Terra: Employee; Self; Pfizer Inc. S.L. Johnson: Employee; Self; Pfizer Inc. S. Huyck: Employee; Self; Merck & Co., Inc. J.P. Mancuso: Employee; Self; Pfizer Inc.. Stock/Shareholder; Self; Pfizer Inc.. Employee; Spouse/Partner; Pfizer Inc.. Stock/Shareholder; Spouse/Partner; Pfizer Inc..
Dapagliflozin Exposure Response in Japanese vs. Non-Japanese Patients with Type 1 Diabetes
Authors: SOKOLOV VICTOR , YAKOVLEVA TATIANA , UEDA SHINYA , PARKINSON JOANNA R. , PENLAND ROBERT C. , BOULTON DAVID W. , TANG WEIFENG 
Published: June 2018

Dapagliflozin (DAPA), an SGLT2 inhibitor, reduces blood glucose by increasing urinary glucose excretion (UGE). The pharmacokinetics and pharmacodynamics of DAPA in Japanese and non-Japanese patients (pts) with type 1 diabetes (T1D) have been evaluated in 2 studies (Japanese: NCT01498185, n=42, DAPA 5, 10 mg or placebo [PBO] for 14 days; Non-Japanese: NCT02582814, n=70, DAPA, 1, 2.5, 5, 10 mg or PBO for 7 days). A clear dose-response for 24-hour UGE was seen in the non-Japanese study but not in the Japanese study. An exposure-response model was used to characterize the relationship between DAPA exposure and 24-hour UGE using a nonlinear mixed-effect modeling approach, and the effect of patient-level characteristics (baseline and Day 7) on this was investigated. Covariates were identified using a stepwise procedure. Average self-monitored blood glucose (SMBG) at Day 7, Day 7 change from baseline in total insulin dose, and baseline eGFR all had a significant effect on UGE; SMBG was the most influential. When these covariates are included, the model fits the data well for both populations (Figure; for the Japanese study, 1 and 2.5 mg data were simulated using median AUC from non-Japanese pts, for 5 and 10 mg median covariate values were from the Japanese study). The lack of clear dose-response in UGE in Japanese pts may primarily be caused by high SMBG, which is likely a result of greater insulin dose reductions in the Japanese study.

Disclosure
V. Sokolov: None. T. Yakovleva: None. S. Ueda: Employee; Self; AstraZeneca. J.R. Parkinson: Employee; Self; AstraZeneca. Stock/Shareholder; Self; AstraZeneca. R.C. Penland: Employee; Self; AstraZeneca. Stock/Shareholder; Self; Novartis Pharmaceuticals Corporation. D.W. Boulton: Employee; Self; AstraZeneca. Stock/Shareholder; Self; Bristol-Myers Squibb Company. W. Tang: Employee; Self; AstraZeneca.
Durability of Glycemic Control with Dapagliflozin vs. Saxagliptin in Patients with Inadequately Controlled Type 2 Diabetes
Authors: BAILEY CLIFFORD J. , PRATO STEFANO DEL , WEI CHERYL , SARAIVA GABRIELA LUPORINI 
Published: June 2018

Type 2 diabetes (T2D) is a progressive disease requiring add-on antihyperglycemic agents to maintain glycemic goals, although how to escalate therapy remains debatable. The benefits of dapagliflozin (DAPA) over saxagliptin (SAXA) on glycemic control (GC) and weight reduction were demonstrated in a post-hoc analysis (NCT01606007). We now evaluate the failure to sustain GC—the slope of ∆A1c over time regression line (coefficient of failure [CoF])—with DAPA or SAXA add-on to metformin (MET). CoF DAPA vs. SAXA was statistically compared directly over 24 weeks (short term; NCT01606007, patients [pts] with ≥1 ∆A1c value at/post week 18) and indirectly (post-hoc analysis of placebo controlled trials) over 102 weeks (long term; NCT00528879 and NCT00121667, pts with ≥3 ∆A1c values from 3 different visits at/post week 20). A1c CoF was lower for DAPA vs. SAXA both at 24 weeks (1.38%/y greater reduction; p=0.009) and 102 weeks (0.37%/y; p=0.04) (Figure). Fewer DAPA- than SAXA-treated pts required rescue medication or discontinued study for failing to achieve GC over 24 weeks (3.4% vs. 9.4%; p=0.0191). Similarly, the placebo adjusted risk ratio of rescue or study discontinuation for DAPA was numerically lower than SAXA over 102 weeks (0.70 vs. 0.74; p=0.68). These results suggest that in T2D pts inadequately controlled on MET, addition of DAPA is associated with significantly greater durability of GC than SAXA over 102 weeks.

Disclosure
C.J. Bailey: Advisory Panel; Self; Abbott, AstraZeneca, Boehringer Ingelheim GmbH, Elcelyx Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk A/S, Sanofi. S. Del Prato: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, GlaxoSmithKline plc., Intarcia Therapeutics, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk A/S, Servier, Sanofi, Takeda Pharmaceuticals U.S.A., Inc.. Research Support; Self; Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., AstraZeneca. Speaker's Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Takeda Pharmaceuticals U.S.A., Inc.. Advisory Panel; Self; Janssen Biotech, Inc., Abbott. C. Wei: Employee; Self; AstraZeneca. G. Luporini Saraiva: Employee; Self; AstraZeneca.
Exploring Hepatic Safety of the Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Vildagliptin in a Real-World Setting
Authors: WILLIAMS RACHAEL , KOTHNY WOLFGANG , SERBAN CARMEN , PALDÁNIUS PÄIVI M. , SCHLIENGER RAYMOND 
Published: June 2018

Since the introduction of DPP-4 inhibitors, vildagliptin has accumulated extensive efficacy/effectiveness and safety data from various meta-analyses of clinical trials, large randomized controlled trials, non-interventional studies, and post-authorization safety studies. In this non-interventional post-authorization study, we explored if vildagliptin is associated with an increased risk of hepatic events vs. other non-insulin antidiabetic drugs (NIADs) in a real-world setting. A cohort study was performed in adult T2DM patients with a vildagliptin or NIAD prescription between January 20and June 2014 with data from five European electronic healthcare databases from the UK (CPRD), Germany and France (IMS), Denmark (OPED) and Sweden (National Registers). Patients with cancer, HIV/AIDS or insulin prior to the index date (date of first vildagliptin or NIAD prescription in the study period) were excluded. Age- and sex-adjusted incidence rate ratios (aIRRs) were estimated in current vildagliptin vs. current other NIAD users using negative binomial regression. We included 738,054 patients, of which 20,973 received vildagliptin (mean follow-up 1.4 years, 28,330 cumulative vildagliptin patient-years). The database-specific aIRR estimates for serious hepatic events were not suggestive of an increased risk with vildagliptin (range of individual aIRR: 0.29-0.55), with two data sources having an upper limit of the 95% confidence interval (CI) &lt;1 (IMS Germany: 0.65; IMS France: 0.63). The aIRR for ALT/AST &gt;3-times upper limit of normal (ULN) together with bilirubin &gt;2-times ULN (only assessed in CPRD) was 0.72 (95% CI: 0.42-1.25). In this real-world setting there was no evidence of an increased risk of hepatic toxicity with vildagliptin exposure compared to other NIADs across five European databases.

Disclosure
R. Williams: Employee; Self; Clinical Practice Research Datalink, London, UK. W. Kothny: Employee; Self; Novartis AG. Stock/Shareholder; Self; Novartis AG. C. Serban: Employee; Self; Novartis AG. Stock/Shareholder; Self; Novartis AG. P.M. Paldánius: Employee; Self; Novartis AG. Stock/Shareholder; Self; Novartis AG. R. Schlienger: Employee; Self; Novartis AG. Stock/Shareholder; Self; Novartis AG.
Discovery of CPL207-280CA, an Effective and Safe GPR40 Agonist for the Treatment of Type 2 Diabetes
Authors: BAZYDLO KATARZYNA , BUDA PAWEL , MACH MATEUSZ , DZIDA RADOSłAW , STELMACH FILIP , DUBIEL KRZYSZTOF K. , PIECZYKOLAN JERZY S. , WIECZOREK MACIEJ 
Published: June 2018

Activation of GPR40 (G-protein coupled receptor 40) in pancreatic beta cells may improve glycaemic control in type 2 diabetes (T2D) through enhancement of glucose-stimulated insulin secretion (GSIS). However, the most clinically advanced GPR40 agonist fasiglifam was withdrawn from phase 3 for its hepatotoxicity resulting presumably from the inhibition of pivotal bile acid transporters. Here we present a potent CPL207-280CA agonist devoid of fasiglifams drawbacks as numerous comparative in vitro and in vivo studies revealed. In Ca2+ influx assay (hGPR40), CPL207-280CA showed higher efficacy than fasiglifam (EC50=70 vs. 250 nM respectively). At 10 µM it showed 3.9-times greater enhancement of GSIS in MIN6 cells. Similarly, in Spraque Dawley (SD) rats and C57BL6 mice challenged with glucose, CPL207-280CA compared with fasiglifam at 10 mg/kg stimulated insulin secretion 2.5-times greater (AUC), without causing hypoglycaemia. CPL207-280CA (at 10 µM) subjected to off-targets’ (Safety47TM, BioMAP) and selectivity analysis showed no off-target activity, as well as in MIN6 and HepG2 cells it exhibited broader range of non toxic doses than its comparator. Finally, in hepatobiliary transporters inhibitory assays (carried out in 10 crucial transporters), CPL207-280CA displayed considerably less propensity than fasiglifam, as favourable IC50 values indicate e.g.: human bile salt export pump (Bsep), &gt;100 and 30 µM; multidrug resistance-associated protein 2 (Mrp2), N.D. and 48 µM; organic anion transporting polypeptide (OATP) 1B1, 17.9 and 0.49 µM; organic anion transporting polypeptide (OATP) 1B3, 43 and 3.4 µM; organic anion transporting polypeptide (OATP) 1A2, 118 and 10.6 µM respectively. We conclude that CPL207-280CA is a potent enhancer of GSIS in model animals, which brings no risk of hypoglycaemia and substantially less risk of hepatotoxicity at therapeutic doses. Therefore we propose CPL207-280CA compound as an effective and safe candidate for the T2D treatment.

Disclosure
K. Bazydlo: Employee; Self; Celon Pharma S.A. P. Buda: Employee; Self; CelonPharma S.A. M. Mach: Employee; Self; Celon Pharma S.A. R. Dzida: Employee; Self; Celon Pharma S.A. F. Stelmach: Employee; Self; Celon Pharma S.A. K.K. Dubiel: Employee; Self; Celon Pharma S.A. J.S. Pieczykolan: Employee; Self; Celon Pharma.S.A. M. Wieczorek: Board Member; Self; Celon Pharma S.A..
The Efficacy of Teneligliptin with Metformin in Drug-Naïve Type 2 Subjects
Authors: CHUDASAMA DIPAK B. , SABOO BANSHI D. , PANCHAL DHARMENDRA , PATEL FENY , SAIYED MAHIRA , HASNANI DHRUVI , CHAVDA VIPUL , CHANDARANA HARDIK , GOKLANI RUTUL 
Published: June 2018

Aim: To assess the efficacy of Teneligliptin with metformin in drug naïve type 2 subjects.
Objective: To assess the efficacy of Teneligliptin with metformin in drug naïve type 2 subjects. Primary outcome observe change in HbA1c, FBS and PPBS from baseline to 48 weeks. Secondary outcome is to note the change in BMI and drug safety.
Method: A retrospective analysis of data from December 2016 till December 2017 was carried out at 4 centers of a chain of Diacare-Diabetes care and Hormone Clinic. The inclusion criteria included newly detected type 2 subjects aged 50.0 +_ 7.0 years, who were Drug naïve with mean HbA1c 8.0% (7%-9%), mean Fasting value 144 mg/dl (+/- 18mg/dl) and mean post meal value 220mg/dl (+/-18mg/dl).
All vital parameters with anthropometric data was analyzed, tabulated and reviewed
Result: N=450 subjects. Reduction in HbA1c after 12 weeks was 1.2% from base line and after 24 weeks it was 1.6% and 1.0% at the end of 48 weeks. 66% of subjects were seen with HbA1c &lt;7% at 24th week. To the rest in whom target was not achieved till 24th weeks, an interventation was added in the form of OHA along with physical exercise and diet.
Drop in BMI at 12 weeks was 0.6 kg/m2, at 24th week it was 0.8 kg/m2 and at 48th week it was 0.5kg/m2. 8% of subjects had an AE-intermittent diarrhea and no SAE was detected.
Conclusion: In real scenario, combination of tenegliptin 20mg with metformin 1000mg was associated with clinically significant reduction in HbA1c.

Disclosure
D.B. Chudasama: None. B.D. Saboo: None. D. Panchal: None. F. Patel: None. M. Saiyed: None. D. Hasnani: None. V. Chavda: None. H. Chandarana: None. R. Goklani: None.